Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vinay Varadan

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Gut|April 27, 2012
A microRNA panel to discriminate carcinomas from high-grade intraepithelial neoplasms in colonoscopy biopsy tissueShuyang Wang, Lei Wang, Nayima Bayaxi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2016
Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast CancerVinay Varadan, Hannah Gilmore, Kristy L S Miskimen, et al.
Cancer Research|February 15, 2020
LIN9 and NEK2 Are Core Regulators of Mitotic Fidelity That Can Be Therapeutically Targeted to Overcome Taxane ResistanceMelyssa S Roberts, Jennifer M Sahni, Morgan S Schrock, et al.
Cancer Research|August 16, 2017
Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET InhibitorsJennifer M Sahni, Sylvia S Gayle, Bryan M Webb, et al.
International Journal of Cancer|August 19, 2015
Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancersVinay Varadan, Sitharthan Kamalakaran, Hannah Gilmore, et al.
Cell Reports|October 10, 2019
Reduction of Global H3K27me<sup>3</sup> Enhances HER2/ErbB2 Targeted TherapyAlison Hirukawa, Salendra Singh, Jarey Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 6, 2015
Reply to Ashktorab et al.: Mutational landscape of colon cancers in African AmericansKishore Guda, Martina L Veigl, Vinay Varadan, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 18, 2022
H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancerMehdi Baratchian, Ritika Tiwari, Sirvan Khalighi, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 14, 2015
Novel recurrently mutated genes in African American colon cancersKishore Guda, Martina L Veigl, Vinay Varadan, et al.
Gastroenterology|July 23, 2022
The Ephrin B2 Receptor Tyrosine Kinase Is a Regulator of Proto-oncogene MYC and Molecular Programs Central to Barrett's NeoplasiaSrividya Venkitachalam, Deepak Babu, Durgadevi Ravillah, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Gut|April 27, 2012
A microRNA panel to discriminate carcinomas from high-grade intraepithelial neoplasms in colonoscopy biopsy tissueShuyang Wang, Lei Wang, Nayima Bayaxi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2016
Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast CancerVinay Varadan, Hannah Gilmore, Kristy L S Miskimen, et al.
Cancer Research|February 15, 2020
LIN9 and NEK2 Are Core Regulators of Mitotic Fidelity That Can Be Therapeutically Targeted to Overcome Taxane ResistanceMelyssa S Roberts, Jennifer M Sahni, Morgan S Schrock, et al.
Cancer Research|August 16, 2017
Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET InhibitorsJennifer M Sahni, Sylvia S Gayle, Bryan M Webb, et al.
International Journal of Cancer|August 19, 2015
Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancersVinay Varadan, Sitharthan Kamalakaran, Hannah Gilmore, et al.
Cell Reports|October 10, 2019
Reduction of Global H3K27me<sup>3</sup> Enhances HER2/ErbB2 Targeted TherapyAlison Hirukawa, Salendra Singh, Jarey Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 6, 2015
Reply to Ashktorab et al.: Mutational landscape of colon cancers in African AmericansKishore Guda, Martina L Veigl, Vinay Varadan, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 18, 2022
H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancerMehdi Baratchian, Ritika Tiwari, Sirvan Khalighi, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 14, 2015
Novel recurrently mutated genes in African American colon cancersKishore Guda, Martina L Veigl, Vinay Varadan, et al.
Gastroenterology|July 23, 2022
The Ephrin B2 Receptor Tyrosine Kinase Is a Regulator of Proto-oncogene MYC and Molecular Programs Central to Barrett's NeoplasiaSrividya Venkitachalam, Deepak Babu, Durgadevi Ravillah, et al.
Pageof 5